AccueilCLIFF • OTCMKTS
add
Cordlife
Dernière clôture
0,070 $
Plage sur l'année
0,069 $ - 0,17 $
Capitalisation boursière
47,08 M SGD
Volume moyen
72,00
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
SGX
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (SGD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 9,46 M | 13,52 % |
Charges d'exploitation | 10,41 M | 1,84 % |
Résultat net | -5,55 M | -11,80 % |
Marge bénéficiaire nette | -58,72 | 1,51 % |
Bénéfice par action | — | — |
EBITDA | -4,29 M | 19,64 % |
Taux d'imposition effectif | -29,22 % | — |
Bilan
Total des actifs
Total du passif
| (SGD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 51,77 M | -15,32 % |
Total des actifs | 201,76 M | -7,08 % |
Total du passif | 97,28 M | -1,42 % |
Total des capitaux propres | 104,48 M | — |
Actions en circulation | 256,31 M | — |
Ratio cours/valeur comptable | 0,17 | — |
Rentabilité des actifs | -6,12 % | — |
Retour sur capitaux | -11,53 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (SGD) | déc. 2025info | Variation Y/Y |
|---|---|---|
Résultat net | -5,55 M | -11,80 % |
Trésorerie (opérations) | -751,00 k | -1 606,82 % |
Trésorerie (invest.) | -6,59 M | 50,34 % |
Trésorerie (financement) | -557,00 k | -106,95 % |
Variation nette en trésorerie | -8,36 M | -45,26 % |
Flux de trésorerie dispo. | -894,00 k | — |
À propos
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
CEO
Date de fondation
2 mai 2001
Site Web
Employés
111
